For over 60 years Novartis has been committed to helping people with cardiovascular disease and we remain steadfast in that commitment to this day.

Novartis researchers have discovered a compound that is showing promise against three parasites that cause three neglected diseases.

Florencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.

Spinal muscular atrophy (SMA) is the most common genetic casue of infant and toddler death. NIBR scientists are trying to make a back up gene take up the slack.

Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.

Novartis innovation and events such as mHealth Challenge enable patients to access data and personal information about their health via mobile devices.

A diminutive protein prompts a closer look at DNA dark matter.

An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.